|By PR Newswire||
|April 11, 2014 08:01 AM EDT||
NEW YORK, April 11, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Regeneron Pharmaceuticals, Inc. Analyst Notes
On April 1, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron), together with Sanofi, announced that the Phase 2 study with alirocumab, an antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) yielded positive results after it demonstrated a bad cholesterol percentage reduction in patients randomized to receive one of three doses of the said antibody every other week combined with statin therapy, as compared with patients receiving placebo. According to the Company, in week 12, the mean percentage reduction in lipoprotein-cholesterol (LDL-C) receiving alirocumab in 50mg, 75mg, and 150mg doses every other week was 55%, 62%, and 72%, respectively, compared with 3% mean reduction rate in the placebo group. Commenting on the results, George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer and Laboratories President, Regeneron, said, "Hypercholesterolemia is a growing problem in Japan and many patients are poorly-controlled on statins. The results from this trial support the efficacy and safety of alirocumab at a range of doses in Japanese patients." The full analyst notes on Regeneron Pharmaceuticals, Inc. will be available to download free of charge at:
Questcor Pharmaceuticals, Inc. Analyst Notes
On March 20, 2014, Questcor Pharmaceuticals, Inc. (Questcor) announced that it is contributing $175,000 to Child Neurology Society (CNS) and Child Neurology Foundation (CNF) to fund the Philip R. Dodge Young Investigator Award, totalling the Company's commitment to the Dodge award to $250,000. Steve Cartt, CEO, Questcor, said, "Questcor's support of the child neurology community is unwavering and we are very pleased to support the Philip R. Dodge Young Investigator Award. Supporting this cornerstone program of the Child Neurology Society will help encourage young scientists to focus their research efforts on initiatives to advance the understanding and treatment of pediatric neurological disorders. Our hope is that these efforts will help pave the way for new and more effective treatments for the many children impacted by these disorders." The full analyst notes on Questcor Pharmaceuticals, Inc. are available to download free of charge at:
Jazz Pharmaceuticals plc Analyst Notes
On March 31, 2014, Jazz Pharmaceuticals plc (Jazz), together with Gentium S.p.A., announced the European commercial launching of Defitelio (defibrotide), the first licensed product designed to treat sever hepatic veno-occlusive disease (severe VOD) in patients over one month of age undergoing haematopoietic stem cell transplantation (HSCT) therapy. According to the Company, severe VOD is a complex and unpredictable disease affecting in over 80% of European patients. Jazz stated that the efficacy of Defitelio to treat sVOD in HSCT patients resulted from a successful phase 3 trial that provided a significant increase of 52% survival rates among patients treated for 100 days compared with patients in the historical control group. The Company informed that Defitelio will be launched in 27 additional European countries starting in 2014 until next year. The full analyst notes on Jazz Pharmaceuticals plc are available to download free of charge at:
Ariad Pharmaceuticals, Inc. Analyst Notes
On March 24, 2014, Ariad Pharmaceuticals, Inc. (Ariad) announced the initiation of the pivotal Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with crizotinib. Ariad informed that ALK in Lung Cancer Trial of AP26113 (ALTA) is designed to determine the safety and efficacy of AP26113 in patients who tested positive for anaplastic lymphoma kinase (ALK+) oncogene. According to the Company, the ALTA trial's primary goal is to achieve an objective response rate (ORR) measured by RECIST criteria, while recording time to response, duration of response, disease control rate, progression-free survival, overall survival, safety and tolerability comes secondary. Ariad added that full patient enrolment is expected in Q3 2015 and the Company expects to report first data from the trial in during the medical meeting in 2015. The full analyst notes on Ariad Pharmaceuticals, Inc. are available to download free of charge at:
BioMarin Pharmaceutical Inc. Analyst Notes
On March 21, 2014, BioMarin Pharmaceutical Inc. (BioMarin) announced the appointment of Dennis J. Slamon, M.D. Ph.D., Clinical/Translational Research Director Revlon /UCLA Women's Cancer Research Program Director, to the Company's Board of Directors. According to the Company, Dr. Slamon won nearly two dozen national and international research awards honoring his scientific endeavors, and has mostly changed the way cancer is treated. Commenting on the appointment, Jean-Jacques Bienaimé, CEO, BioMarin, said, "I am delighted that Dr. Slamon will be joining BioMarin's board. His experience in translating discovery into medicines is aligned with our mission to treat patients with unmet medical needs based on a specific knowledge of the molecular basis of their disease. As BioMarin builds its pipeline of early and late stage therapies, Dr. Slamon's support will help us achieve success in the clinic." The full analyst notes on BioMarin Pharmaceutical Inc. are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Feb. 21, 2017 04:30 AM EST Reads: 1,391
SYS-CON Events announced today that Linux Academy, the foremost online Linux and cloud training platform and community, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Linux Academy was founded on the belief that providing high-quality, in-depth training should be available at an affordable price. Industry leaders in quality training, provided services, and student certification passes, its goal is to c...
Feb. 21, 2017 03:45 AM EST Reads: 849
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Feb. 21, 2017 03:30 AM EST Reads: 3,562
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, discussed how leveraging the Industrial Internet and...
Feb. 21, 2017 03:30 AM EST Reads: 7,547
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
Feb. 21, 2017 03:00 AM EST Reads: 1,589
910Telecom exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and exchanges.
Feb. 21, 2017 02:45 AM EST Reads: 1,331
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, discussed how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a practic...
Feb. 21, 2017 02:00 AM EST Reads: 4,564
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and micro services. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your contain...
Feb. 21, 2017 01:15 AM EST Reads: 3,257
The modern software development landscape consists of best practices and tools that allow teams to deliver software in a near-continuous manner. By adopting a culture of automation, measurement and sharing, the time to ship code has been greatly reduced, allowing for shorter release cycles and quicker feedback from customers and users. Still, with all of these tools and methods, how can teams stay on top of what is taking place across their infrastructure and codebase? Hopping between services a...
Feb. 21, 2017 01:00 AM EST Reads: 6,263
Niagara Networks exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
Feb. 21, 2017 12:30 AM EST Reads: 707
Zerto exhibited at SYS-CON's 18th International Cloud Expo®, which took place at the Javits Center in New York City, NY, in June 2016. Zerto is committed to keeping enterprise and cloud IT running 24/7 by providing innovative, simple, reliable and scalable business continuity software solutions. Through the Zerto Cloud Continuity Platform™, organizations can seamlessly move and protect virtualized workloads between public, private and hybrid clouds. The company’s flagship product, Zerto Virtual...
Feb. 21, 2017 12:30 AM EST Reads: 1,034
WebRTC is about the data channel as much as about video and audio conferencing. However, basically all commercial WebRTC applications have been built with a focus on audio and video. The handling of “data” has been limited to text chat and file download – all other data sharing seems to end with screensharing. What is holding back a more intensive use of peer-to-peer data? In her session at @ThingsExpo, Dr Silvia Pfeiffer, WebRTC Applications Team Lead at National ICT Australia, looked at differ...
Feb. 20, 2017 10:15 PM EST Reads: 6,195
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...
Feb. 20, 2017 10:15 PM EST Reads: 3,337
For basic one-to-one voice or video calling solutions, WebRTC has proven to be a very powerful technology. Although WebRTC’s core functionality is to provide secure, real-time p2p media streaming, leveraging native platform features and server-side components brings up new communication capabilities for web and native mobile applications, allowing for advanced multi-user use cases such as video broadcasting, conferencing, and media recording.
Feb. 20, 2017 10:15 PM EST Reads: 5,917
"Plutora provides release and testing environment capabilities to the enterprise," explained Dalibor Siroky, Director and Co-founder of Plutora, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
Feb. 20, 2017 09:15 PM EST Reads: 4,509